UBC Faculty Research and Publications

Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria Conroy, Andrea L; Hawkes, Michael T; Elphinstone, Robyn; Opoka, Robert O; Namasopo, Sophie; Miller, Christopher; John, Chandy C; Kain, Kevin C


Background: Chitinase-3-like 1 (CHI3L1) is a glycoprotein elevated in paediatric severe malaria, and an emerging urinary biomarker of acute kidney injury (AKI). Based on the hypothesis that elevated CHI3L1 levels in malaria are associated with disease severity, the relationship between plasma CHI3L1 levels, AKI and mortality was investigated in Ugandan children enrolled in a clinical trial evaluating inhaled nitric oxide (iNO) as an adjunctive therapy for severe malaria. Methods: Plasma CHI3L1 levels were measured daily for 4 days in children admitted to hospital with severe malaria and at day 14 follow up. AKI was defined using the Kidney Disease: Improving Global Outcomes consensus criteria. This is a secondary analysis of a randomized double-blind placebo-controlled trial of iNO versus placebo as an adjunctive therapy for severe malaria. Inclusion criteria were: age 1–10 years, and selected criteria for severe malaria. Exclusion criteria included suspected bacterial meningitis, known chronic illness including renal disease, haemoglobinopathy, or severe malnutrition. iNO was administered by non-rebreather mask for up to 72 h at 80 ppm. Results: CHI3L1 was elevated in patients with AKI and remained higher over hospitalization (p 

Item Media

Item Citations and Data


Attribution 4.0 International (CC BY 4.0)

Usage Statistics